131 related articles for article (PubMed ID: 8881840)
1. Atherogenic risk reduction in patients with dyslipidaemia. comparison between bezafibrate and lovastatin.
Sinzinger H; Pirich C; Kondor P; Etti H
Eur Heart J; 1995 Nov; 16(11):1491-501. PubMed ID: 8881840
[TBL] [Abstract][Full Text] [Related]
2. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.
Hidalgo L; Zambrana JL; Blanco-Molina A; López-Granados A; Concha M; Casares J; Jiménez-Pérez J; López-Miranda J; Pérez-Jiménez F
J Heart Lung Transplant; 1995; 14(3):461-7. PubMed ID: 7654731
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Jeck T; Riesen WF; Keller U
Diabet Med; 1997 Jul; 14(7):564-70. PubMed ID: 9223394
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients.
Zambrana JL; Velasco F; Castro P; Concha M; Vallés F; Montilla P; Jimenéz-Perepérez JA; López-Miranda J; Pérez-Jiménez F
Am J Cardiol; 1997 Oct; 80(7):836-40. PubMed ID: 9381994
[TBL] [Abstract][Full Text] [Related]
5. [A comparison of bezafibrate and lovastatin treatment at the usual doses in post-heart transplant hyperlipemia].
Zambrana García JL; López Miranda J; Anguita Sánchez M; Blanco Cerrada J; Vallés Belsúe F; Casares Mediavilla J; Muñoz Carvajal I; Jiménez Perepérez JA; Pérez Jiménez F
Rev Esp Cardiol; 1996 Dec; 49(12):892-8. PubMed ID: 9026840
[TBL] [Abstract][Full Text] [Related]
6. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Goa KL; Barradell LB; Plosker GL
Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
[TBL] [Abstract][Full Text] [Related]
7. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
[TBL] [Abstract][Full Text] [Related]
8. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
Barbir M; Hunt BJ; Galloway D; Taylor A; Ilsley C; Mitchell A; Yacoub M
Clin Cardiol; 1994 Feb; 17(2):59-64. PubMed ID: 8162627
[TBL] [Abstract][Full Text] [Related]
9. Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia.
Zambrana JL; López-Miranda J; Blanco A; Arizón JM; Jansen S; Paniagua JA; Jimenéz-Perepérez JA; Concha M; Pérez-Jiménez F
J Heart Lung Transplant; 1998 Dec; 17(12):1213-9. PubMed ID: 9883763
[TBL] [Abstract][Full Text] [Related]
10. Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia.
Hutchesson AC; Moran A; Jones AF
J Clin Pharm Ther; 1994 Dec; 19(6):387-9. PubMed ID: 7876371
[TBL] [Abstract][Full Text] [Related]
11. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
Yeshurun D; Abukarshin R; Elias N; Lanir A; Naschitz JE
Clin Ther; 1993; 15(2):355-63. PubMed ID: 8519043
[TBL] [Abstract][Full Text] [Related]
12. Lovastatin versus bezafibrate: efficacy, tolerability, and effect on urinary mevalonate.
Beil FU; Schrameyer-Wernecke A; Beisiegel U; Greten H; Karkas JD; Liou R; Alberts AW; Eckardt HG; Till AE
Cardiology; 1990; 77 Suppl 4():22-32. PubMed ID: 2073669
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
Schumacher M; Eber B; Silberbauer K; Breier C; Stühlinger W; Schmidt P; Gaul G; Klein W
Acta Med Austriaca; 1992; 19(5):140-4. PubMed ID: 1298143
[TBL] [Abstract][Full Text] [Related]
14. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
[TBL] [Abstract][Full Text] [Related]
15. Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus.
Winocour PH; Durrington PN; Bhatnagar D; Ishola M; Arrol S; Lalor BC; Anderson DC
Diabet Med; 1990; 7(8):736-43. PubMed ID: 2147637
[TBL] [Abstract][Full Text] [Related]
16. Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia.
Ko GT; Mak TW; Yeung VT; Chan DC; Lam CW; Tsang LW; Chow CC; Cockram CS
J Clin Pharmacol; 1998 Oct; 38(10):912-7. PubMed ID: 9807971
[TBL] [Abstract][Full Text] [Related]
17. [Comparison about the efficacy and tolerability between simvastatin and bezafibrate in the treatment of hypercholesterolemia].
Bruckert E; Truffert J; De Gennes JL
Ann Med Interne (Paris); 1991; 142(7):505-10. PubMed ID: 1789528
[TBL] [Abstract][Full Text] [Related]
18. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
Papadakis JA; Ganotakis ES; Jagroop IA; Winder AF; Mikhailidis DP
Int J Cardiol; 1999 Jun; 69(3):237-44. PubMed ID: 10402106
[TBL] [Abstract][Full Text] [Related]
19. Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation.
Lintott CJ; Scott RS; Sharpe DN; Nye ER; Charleson H; French JK; White HD; Reuben S; Maling TJ; Lewis GR
Med J Aust; 1991 Oct; 155(7):433-6. PubMed ID: 1921811
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Bruckert E; De Gennes JL; Malbecq W; Baigts F
Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
